Institute for Systems Biology, 401 Terry Ave N, Seattle, WA, 98109, USA.
Department of Biostatistics, University of Washington, Seattle, WA, USA.
Sci Rep. 2020 Oct 1;10(1):16275. doi: 10.1038/s41598-020-73451-z.
We analyzed 1196 proteins in longitudinal plasma samples from participants in a commercial wellness program, including samples collected pre-diagnosis from ten cancer patients and 69 controls. For three individuals ultimately diagnosed with metastatic breast, lung, or pancreatic cancer, CEACAM5 was a persistent longitudinal outlier as early as 26.5 months pre-diagnosis. CALCA, a biomarker for medullary thyroid cancer, was hypersecreted in metastatic pancreatic cancer at least 16.5 months pre-diagnosis. ERBB2 levels spiked in metastatic breast cancer between 10.0 and 4.0 months pre-diagnosis. Our results support the value of deep phenotyping seemingly healthy individuals in prospectively inferring disease transitions.
我们分析了商业健康计划参与者的 1196 种纵向血浆样本中的蛋白质，包括从 10 名癌症患者和 69 名对照者中采集的样本。对于最终被诊断患有转移性乳腺癌、肺癌或胰腺癌的 3 个人，早在诊断前 26.5 个月，CEACAM5 就是一个持续的纵向异常值。CALCA 是甲状腺髓样癌的生物标志物，在至少 16.5 个月前诊断出转移性胰腺癌时过度分泌。ERBB2 水平在转移性乳腺癌中在诊断前 10.0 至 4.0 个月之间飙升。我们的结果支持对看似健康的个体进行深入表型分析以预测疾病进展的价值。
